Lina Badimon
Immunology · 2014–2020
A researcher in the Science corpus: 6 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 44 citations into it
- Epidemiology — 40 citations into it
Whom Lina Badimon trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Lina Badimon's perspective
Ordered by how strongly the researchers Lina Badimon trusts endorse each paper. Same corpus, a different order for every researcher.
- C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. (New England Journal of Medicine)
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (New England Journal of Medicine)
- Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association (Circulation)
- Genetic Risk, Coronary Heart Disease Events, and the Clinical Benefit of Statin Therapy (The Lancet)
- Genetic variants associated with Lp(a) lipoprotein level and coronary disease. (New England Journal of Medicine)
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. (The Lancet)
- Macrophage Phenotype and Function in Different Stages of Atherosclerosis (Circulation Research)
- C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. (New England Journal of Medicine)
- Rosuvastatin in older patients with systolic heart failure. (Current Atherosclerosis Reports)
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (Cardiovascular Drugs and Therapy)
Their papers
- An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. (2020) — 767 citations
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) — 4,665 citations
- Atherosclerosis (2019) — 2,081 citations
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016) — 779 citations
- Thrombosis formation on atherosclerotic lesions and plaque rupture (2014) — 621 citations
- 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous (2014) — 3,398 citations